{
    "ticker": "HEPS",
    "name": "Hepion Pharmaceuticals, Inc.",
    "description": "Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic liver diseases, particularly non-alcoholic steatohepatitis (NASH) and other liver-related disorders. Founded in 2015 and headquartered in Edison, New Jersey, Hepion's mission is to address the unmet medical needs of patients suffering from liver diseases through the development of novel therapeutics. The company's lead product candidate, CRV431, is a first-in-class, oral therapeutic designed to target multiple mechanisms of liver injury and fibrosis. Hepion is committed to advancing the understanding of liver disease and aims to improve treatment outcomes for patients through rigorous clinical trials and research. In addition to CRV431, Hepion is exploring other compounds and collaborations that may enhance its pipeline and contribute to the fight against liver disease. The company is actively engaged with the scientific community and regulatory agencies to bring its promising therapies to market while ensuring the highest standards of safety and efficacy.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Edison, New Jersey, USA",
    "founded": "2015",
    "website": "https://www.hepionpharma.com",
    "ceo": "David M. Pritchard",
    "social_media": {
        "twitter": "https://twitter.com/HepionPharma",
        "linkedin": "https://www.linkedin.com/company/hepion-pharmaceuticals/"
    },
    "investor_relations": "https://www.hepionpharma.com/investors/",
    "key_executives": [
        {
            "name": "David M. Pritchard",
            "position": "CEO"
        },
        {
            "name": "Shawn M. K. McDonald",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CRV431"
            ]
        }
    ],
    "seo": {
        "meta_title": "Hepion Pharmaceuticals, Inc. | Innovating Liver Disease Therapies",
        "meta_description": "Explore Hepion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for liver diseases. Learn about our lead candidate CRV431 and our commitment to improving patient outcomes.",
        "keywords": [
            "Hepion Pharmaceuticals",
            "CRV431",
            "Liver Disease",
            "NASH",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Hepion Pharmaceuticals known for?",
            "answer": "Hepion Pharmaceuticals is known for developing innovative therapies for chronic liver diseases, particularly non-alcoholic steatohepatitis (NASH)."
        },
        {
            "question": "Who is the CEO of Hepion Pharmaceuticals?",
            "answer": "David M. Pritchard is the CEO of Hepion Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Hepion Pharmaceuticals headquartered?",
            "answer": "Hepion Pharmaceuticals is headquartered in Edison, New Jersey, USA."
        },
        {
            "question": "What is Hepion's lead product candidate?",
            "answer": "Hepion's lead product candidate is CRV431, an oral therapeutic targeting liver injury and fibrosis."
        },
        {
            "question": "When was Hepion Pharmaceuticals founded?",
            "answer": "Hepion Pharmaceuticals was founded in 2015."
        }
    ],
    "competitors": [
        "GILD",
        "MRNA",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "BIIB",
        "REGN",
        "CELG"
    ]
}